Effect of a computer-guided, quality improvement program for cardiovascular disease risk management in primary health care: The treatment of cardiovascular risk using electronic decision support cluster-randomized trial

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 1, 2015, Pages 87-95

  Peiris, David ^a   Usherwood, Tim ^b   Panaretto, Kathryn ^d   Harris, Mark ^e   Hunt, Jennifer ^f   Redfern, Julie ^a   Zwar, Nicholas ^e   Colagiuri, Stephen ^a   Hayman, Noel ^d   Lo, Serigne ^a   Patel, Bindu ^a   Lyford, Marilyn ^a   Macmahon, Stephen ^a   Neal, Bruce ^a   Sullivan, David ^c   Cass, Alan ^g   Jackson, Rod ^h   Patel, Anushka ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Sydney Medical School University of Sydney ^*  (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Australia   (Australia)

^g MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^h UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cardiovascular diseases; Primary health care; Quality improvement

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; AUSTRALIAN; CARDIOVASCULAR DISEASE; COMPUTER GUIDED QUALITY IMPROVEMENT PROGRAM; COMPUTER PROGRAM; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; ELECTRONIC DECISION SUPPORT; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK MANAGEMENT; STAFF TRAINING; TORRES STRAIT ISLANDER; TOTAL QUALITY MANAGEMENT; AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED THERAPY; HEALTH CARE QUALITY; MIDDLE AGED; PREDICTIVE VALUE; PREVENTIVE HEALTH SERVICE; RISK ASSESSMENT; STANDARDS; TIME; TREATMENT OUTCOME;

ADULT; AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; PRIMARY HEALTH CARE; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; THERAPY, COMPUTER-ASSISTED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927633912     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.114.001235     Document Type: Article

References (38)

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee Y Y, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero A P, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk G V, Polinder S, Pope CA III, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-2223. doi: 10.1016/S0140-6736 (12) 61689-4.
2. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365:434-441. doi: 10.1016/S0140-6736 (05) 17833-7.
3. Jackson R, Wells S, Rodgers A. Will screening individuals at high risk of cardiovascular events deliver large benefits?Yes. BMJ. 2008;337:a1371.
4. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679-686. doi: 10.1016/S0140-6736 (06) 69252-0.
5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-137. doi: 10.1097/HJR.0b013e3283294b1d.
6. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP; REACH Investigators. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009;8:104-111. doi: 10.1097/HPC.0b013e3181b8395d.
7. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243. doi: 10.1016/S0140-6736 (11) 61215-4.
8. Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Massó-González EL, Jiménez FJ, Perk J, Steg PG, De Backer G, Rodríguez-Artalejo F. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143-2152. doi: 10.1093/eurheartj/ehr080.
9. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S; PURE (Prospective Urban Rural Epidemiology) Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-968. doi: 10.1001/jama.2013.184182.
10. Webster R, Heeley E, Peiris D, Bayram C, Cass A, Patel A. Identifying the gaps in cardiovascular risk management. Med J Aust. 2009;191:324-329
11. Heeley E, Peiris D, Patel A, Cass A, Weekes A, Morgan C, Anderson C, Chalmers J. Cardiovascular risk perception and the evidence practice gap in Australian general practice (the AUSHEART study). Med J Aust. 2010;192:254-259
12. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J. 2013;34:1262-1269. doi: 10.1093/eurheartj/ehs481.
13. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, Sam J, Haynes RB. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes a systematic review. JAMA. 2005;293:1223-1238.
14. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ. 2005;330:765. doi: 10.1136/bmj.38398.500764.8F.
15. Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, Samsa G, Hasselblad V, Williams JW, Musty MD, Wing L, Kendrick AS, Sanders GD, Lobach D. Effect of clinical decision-support systems: a systematic review. Ann Intern Med. 2012;157:29-43. doi: 10.7326/0003-4819-157-1-201207030-00450.
16. Roshanov PS, Fernandes N, Wilczynski JM, Hemens BJ, You JJ, Handler SM, Nieuwlaat R, Souza NM, Beyene J, Van Spall HG, Garg AX, Haynes RB. Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ. 2013;346:f657.
17. Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, O'Brien MA, Johansen M, Grimshaw J, Oxman AD. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012;6:CD000259. doi: 10.1002/14651858. CD000259.pub3.
18. Community Services Preventive Services Taskforce. Guide to community preventive services-cardiovascular disease prevention and control: Clinical decision-support systems. http://www.thecommunityguide.org/cvd/CDSS.html Accessed December 15, 2014.
19. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. http://strokefoundation. com. au/site/media/AbsoluteCVD-GL-webready.pdf Accessed December 15, 2014.
20. Peiris D, Usherwood T, Panaretto K, Harris M, Hunt J, Patel B, Zwar N, Redfern J, Macmahon S, Colagiuri S, Hayman N, Patel A. The Treatment of cardiovascular Risk in Primary care using Electronic Decision supOrt (TORPEDO) study-intervention development and protocol for a cluster randomised, controlled trial of an electronic decision support and quality improvement intervention in Australian primary healthcare. BMJ Open. 2012;2. doi: 10.1136/bmjopen-2012-002177.
21. Peiris D P, Joshi R, Webster RJ, Groenestein P, Usherwood TP, Heeley E, Turnbull FM, Lipman A, Patel AA. An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation. J Med Internet Res. 2009;11:e51. doi: 10.2196/jmir.1258.
22. Wells S, Kerr A, Eadie S, Wiltshire C, Jackson R. 'Your Heart Forecast': a new approach for describing and communicating cardiovascular risk? Heart. 2010;96:708-713. doi: 10.1136/hrt.2009.191320.
23. Peiris D, Agaliotis M, Patel B, Patel A. Validation of a general practice audit and data extraction tool. Aust Fam Physician. 2013;42:816-819.
24. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-362.
25. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet. 2005;365:1591-1595. doi: 10.1016/S0140-6736 (05) 66461-6.
26. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345-351. doi: 10.1161/01. HYP.0000200702.76436.4b.
27. Berwick DM. The question of improvement. JAMA. 2012;307:2093-2094. doi: 10.1001/jama.2012.4146.
28. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362:1225-1230. doi: 10.1016/S0140-6736 (03) 14546-1.
29. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, Manns B, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379:2252-2261. doi: 10.1016/S0140-6736 (12) 60480-2.
30. Berwanger O, Guimarães HP, Laranjeira LN, Cavalcanti AB, Kodama AA, Zazula AD, Santucci E V, Victor E, Tenuta M, Carvalho V, Mira VL, Pieper KS, Weber B, Mota LH, Peterson ED, Lopes RD; Bridge-Acs Investigators. Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial. JAMA. 2012;307:2041-2049. doi: 10.1001/jama.2012.413.
31. Britt H, Miller GC, Henderson J, Charles J, Valenti L, Harrison C, Bayram C, Zhang C, Pollack AJ, O'Halloran J, Pan Y. General Practice Activity in Australia 2011-12. General Practice Series No. 31. Sydney: Sydney University Press; 2012.
32. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander health services report, 2010-11: OATSIH Services Reporting-Key Results. Cat. No. IHW 79. Canberra: AIHW; 2012.
33. Schoen C, Osborn R, Squires D, Doty M, Rasmussen P, Pierson R, Applebaum S. A survey of primary care doctors in ten countries shows progress in use of health information technology, less in other areas. Health Aff (Millwood). 2012;31:2805-2816. doi: 10.1377/hlthaff.2012.0884.
34. Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010;363:501-504. doi: 10.1056/NEJMp1006114.
35. Australian Institute of Health and Welfare. Cardiovascular Disease: Australian Facts 2011. Cardiovascular Disease Series. Cat. No. CVD 53. Canberra: AIHW; 2011.
36. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
37. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
38. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.